Arrowhead Pharmaceuticals Inc.

Latest Arrowhead Pharmaceuticals Inc. News and Updates

  • uploads///AdobeStock_
    Company & Industry Overviews

    How Analysts View Arrowhead Pharmaceuticals

    In Q2, Arrowhead Pharmaceuticals reported revenues of $48.15 million—a YoY rise of 7,305.95%—ahead of the consensus estimate by $5.19 million.

    By Margaret Patrick
  • uploads///ARWR TRiM platform
    Company & Industry Overviews

    What Led to Arrowhead Pharmaceuticals’ Revenue Surge in 2017?

    Arrowhead Pharmaceuticals’ therapeutic candidate ARO-LUNG1 is being developed for an undisclosed disease of the lung. This is the first candidate to utilize the company’s TRiM platform.

    By Kenneth Smith
  • uploads///Hepatitis B virus life cycle
    Company & Industry Overviews

    Arrowhead’s Candidates for Hepatitis B, Cardiovascular Diseases

    ARO-HBV is Arrowhead Pharmaceuticals’ (ARWR) investigational drug candidate for treating chronic hepatitis B infection.

    By Kenneth Smith
  • uploads///ARWR Drug Pipeline
    Company & Industry Overviews

    Taking a Closer Look at Arrowhead Pharmaceuticals’ TRIM Platform

    Arrowhead Pharmaceuticals’ (ARWR) prior efforts were aimed at clinical programs that utilized the dynamic polyconjugate (or DPC), also called the EX1 delivery vehicle.

    By Kenneth Smith
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.